ArticleFrontiers in endocrinology2026
Short-term biochemical outcomes after microwave ablation versus parathyroidectomy for primary hyperparathyroidism: an IPTW analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the short-term biochemical efficacy and safety of microwave ablation (MWA) and parathyroidectomy (PTX) in patients with primary hyperparathyroidism (PHPT), and to identify independent predictors of treatment failure. Materials and methods: This retrospective cohort study included 173 consecutive patients with PHPT treated with MWA (n = 46) or PTX (n = 127) between January 2019 and January 2025. Covariate-balancing propensity score-derived inverse probability of treatment weighting (CBPS-IPTW) was used to balance baseline characteristics. Longitudinal changes in parathyroid hormone (PTH), calcium, and phosphorus were assessed using IPTW-weighted linear mixed-effects models, whereas biochemical treatment failure and safety outcomes were compared using weighted logistic regression with robust standard errors. IPTW-weighted Kaplan-Meier and Cox analyses were exploratory, and factors associated with treatment failure were evaluated using Firth penalized logistic regression. Results: After weighting, all covariates were well balanced, with absolute standardized mean differences <0.01. Both treatments produced substantial biochemical improvement. A significant treatment-by-time interaction was observed for PTH (P < 0.001), whereas calcium and phosphorus trajectories did not differ significantly. The weighted risks of treatment failure were 23.8% after PTX and 35.9% after MWA [odds ratio (OR), 1.80; 95% confidence interval (CI), 0.74-4.39], with an absolute risk difference of 12.1 percentage points (95% CI, -7.3 to 31.6). Exploratory Cox analysis showed no significant difference in documented treatment failure (hazard ratio, 1.73; 95% CI, 0.82-3.64). Weighted hypocalcemia risks were 9.2% and 15.5%, respectively (OR, 1.81; 95% CI, 0.50-6.56). Each doubling of baseline PTH was associated with approximately twofold higher odds of treatment failure (OR, 2.02; 95% CI, 1.39-4.09). Conclusion: Both MWA and PTX produced substantial short-term biochemical improvement. No significant difference in 6-month treatment failure was detected after CBPS-IPTW adjustment; however, wide confidence intervals precluded conclusions of equivalence or non-inferiority. Baseline PTH may help identify patients at increased risk of incomplete biochemical response, and MWA may be considered for carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.